Structured evidence table for Quercetin Blood Pressure Meta-Analysis, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Quercetin Blood Pressure Meta-Analysis | These abnormalities result from deficient insulin secretion (type 1), resistance to the action of insulin (type 2), or both []. | 3 | Muharib Dina (2026) | Modulatory Effects of Polyphenols on Altered Leukocyte Functions in Thromboinflammation and Diabetes Mellitus |
| Quercetin Blood Pressure Meta-Analysis | The global prevalence of DM has increased dramatically in recent decades, particularly through an increase in type 2 DM (T2DM) driven by a global rise in obesity. | 3 | Muharib Dina (2026) | Modulatory Effects of Polyphenols on Altered Leukocyte Functions in Thromboinflammation and Diabetes Mellitus |
| Quercetin Blood Pressure Meta-Analysis | In addition to traditional cardiovascular risk factors, DM is recognized as a thromboinflammatory condition characterized by dysregulated haemostasis and chronic low-grade inflammation [,]. | 3 | Muharib Dina (2026) | Modulatory Effects of Polyphenols on Altered Leukocyte Functions in Thromboinflammation and Diabetes Mellitus |
| Quercetin Blood Pressure Meta-Analysis | 1 2 3 4 5 Diabetes mellitus (DM) is a group of metabolic disorders characterized by persistent hyperglycaemia defined as a fasting plasma glucose level ≥ 7.0 mmol/L or a random plasma glucose level ≥ 11.1 mmol/L in presence of symptoms or signs of DM or hemoglobin A1c (HbA1c) exceeding 48 mmol/mol []. | 3 | Muharib Dina (2026) | Modulatory Effects of Polyphenols on Altered Leukocyte Functions in Thromboinflammation and Diabetes Mellitus |
| Quercetin Blood Pressure Meta-Analysis | Epidemiological studies indicate that CRS affects a substantial proportion of patients, with an estimated prevalence of up to 0.4% in the general population and 2–3% in individuals with diabetes and heart failure, and is associated with increased morbidity and mortality [,]. | 3 | Carollo Caterina (2026) | Nature’s Bioactives in Cardiorenal Syndrome: Polyphenols at the Crossroads—Preclinical Insights into Redox, Inflammation, and Mitochondrial Protection |
| Quercetin Blood Pressure Meta-Analysis | Most preclinical studies investigating polyphenolic interventions have focused on type IV and type V CRS, particularly diabetes-induced chronic kidney disease with associated cardiovascular dysfunction [,]. | 3 | Carollo Caterina (2026) | Nature’s Bioactives in Cardiorenal Syndrome: Polyphenols at the Crossroads—Preclinical Insights into Redox, Inflammation, and Mitochondrial Protection |
| Quercetin Blood Pressure Meta-Analysis | Specifically, gut dysbiosis leads to an increased intestinal permeability (leaky gut), allowing the translocation of microbiota-derived uremic toxins (such as p-cresyl sulfate and TMAO) into the systemic circulation [,]. | 3 | Carollo Caterina (2026) | Nature’s Bioactives in Cardiorenal Syndrome: Polyphenols at the Crossroads—Preclinical Insights into Redox, Inflammation, and Mitochondrial Protection |
| Quercetin Blood Pressure Meta-Analysis | 1 2 3 4 5 6 7 1 2 1 2 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 Figure 1 Cardiorenal syndromes (CRS) describe the complex bidirectional interaction between the heart and the kidneys, whereby acute or chronic dysfunction of one organ induces structural and functional impairment of the other []. | 3 | Carollo Caterina (2026) | Nature’s Bioactives in Cardiorenal Syndrome: Polyphenols at the Crossroads—Preclinical Insights into Redox, Inflammation, and Mitochondrial Protection |
Source documents